ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Clinical trial NCT03595917 · RECRUITING

Trial details

NCT number: NCT03595917
Sponsor: Marlise Luskin, MD
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

Start date: 2018-07-24
Primary completion: 2026-11-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.